Akebia Therapeutics, Inc. AKBA

0.90 (0.02) (2.17%) as of 25 Sep
Market cap
$254.7M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Net Income (29.67) (20.51) (5.34) (15.90)

+8 more TTM periods

Depreciation & Amortization 1.55 1.28 1.27 10.29
Non Cash Items (Other) 49.34 57.94 55.60 46.64
Accounts Receivable Change 18.59 (1.97) (14.14) (36.31)
Change in inventories (13.71) (20.71) (23.12) (14.20)
Change in payables and accrued liability 22.75 45.32 51.61 34.53
Change in other assets and liabilities (7.29) (0.98) 2.13 7.35
Operating Cash Flow 41.55 60.37 67.99 32.40
Capital expenditures (1.29) (0.33) (0.12) (0.05)
Investing cash flow (12.09) (8.14) (7.93) (0.05)
Repayment/Issuance of Debt (Net) — — 9.54 9.54
Equity Repurchase (Common, Net) 4.65 3.05 68.36 90.62
Other financial activities (15.85) (5.99) (4.97) (0.06)
Financing cash flow (11.20) (2.94) 72.93 100.10
Change in Cash 18.26 49.29 132.99 132.45
Beginning Cash 186.54 186.54 53.55 53.55
Ending Cash 204.80 235.83 186.54 186.00
Stock Based Compensation 13.31 12.76 11.28 9.78
Dividends Paid (Common) 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total) 20.33 21.66 16.47 (8.63)
Issuance/Purchase of Shares 4.65 3.05 68.36 90.62

Fold the line items

In millions of $ except per-share values · columns are period end dates